34.7 C
Vientiane
Saturday, August 2, 2025
spot_img

/DISREGARD RELEASE: Antengene Corporation Limited/

This Week

We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.

Latest article